How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both art and formula.

Hartaj Singh on LinkedIn:

https://www.linkedin.com/in/hartaj-s-35614670/

Check out Hartaj's newsletter:

The Biotech Capital Compass - https://hartajsingh1.substack.com/

Subscribe to the Cures & Capital podcast on YouTube, Apple Podcasts, and Spotify!

Make sure to follow us on LinkedIn:

linkedin.com/company/cures-capital-podcast

Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.